Tylenol Use in Pregnancy May Reduce Daughters’ Fertility, Study Finds
A study in Denmark found that prenatal Tylenol (acetaminophen) exposure may reduce ovarian reserves and uterine size in daughters, but long-term effects on fertility are unknown. Researchers studied 302 infants and 1,210 girls, finding smaller ovaries and uteruses in those exposed. The FDA and ACOG state no clear evidence of harm, while Kenvue, which owns Tylenol, defends its safety. Texas sued Kenvue over advertising claims, with one case ongoing.
How this was made
The 30-second read
Why it matters
The study fuels debate, but regulators (FDA, ACOG) maintain current safety guidance. Kenvue faces a revived lawsuit alleging deceptive advertising.
Market read
Kenvue stock reacts to legal risk; broader consumer‑health sector may see heightened caution.
What to watch
Potential for settlement or dismissal could limit long‑term impact; broader market may absorb the news.
Background
A Danish observational study linked prenatal Tylenol exposure to reduced ovarian size in girls, prompting renewed public and regulatory scrutiny of the drug.
Ticker impact
Kenvue shares fell more than 3% after a judge allowed a consumer‑protection claim related to Tylenol advertising to proceed.
short‑term downside pressure, potential further decline if additional claims proceed
The lawsuit revives scrutiny of Tylenol, a core product; investors may view the risk as material, but the move is limited to a few percent.
Market effects
Consumer health products may face heightened regulatory and litigation risk.
U.S. consumer‑health sector sentiment could soften.
Limited to Kenvue; no broader macro impact.
Counterpoint
The share dip may be overblown; Tylenol remains a best‑selling product with strong demand.
Key entities
- CompanyKenvue
Owner of the Tylenol brand, subject of the lawsuit and share decline.
- RegulatorFDA
Continues to monitor Tylenol use in pregnancy, no change in guidance.
